The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
This is the first drug to receive a recommendation for this preventative indication in the European Union
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Diversifying its portfolio to include late-phase antiviral agent
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Subscribe To Our Newsletter & Stay Updated
